Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

α-Vitamin E [59-02-9]

Imprimer

Référence HY-N0683-1g

Conditionnement : 1g

Marque : MedChemExpress

Demander plus d'informations

Description

α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant^[1]^[2].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	3.658 μg/mL Compound: alpha-tocopherol	Antioxidant activity in rat erythrocytes assessed as inhibition of phenyl hydrazine-induced haemolysis after 1 hr Antioxidant activity in rat erythrocytes assessed as inhibition of phenyl hydrazine-induced haemolysis after 1 hr	[PMID: 23395966]
Fibroblast	EC₅₀	234 nM Compound: 2, Vitamin E	Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
Fibroblast	GI₅₀	≥300 μM Compound: 2, Vitamin E	Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
Fibroblast	EC₅₀	>500 nM Compound: alpha-TOH	Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay Inhibition of erastin-induced cell death in FRDA patient-derived fibroblast assessed as depletion of cellular ATP incubated for 12 hrs followed by erastin stimulation and measured after by luciferase-linked ATPase enzymatic assay	[PMID: 33214825]
HepG2	IC₅₀	>300 μM Compound: alpha-TOH	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
HL-60	IC₅₀	255 μM Compound: Vitamin E	Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay Antioxidant activity against TPA-induced ROS production in human HL60 cells by 2',7'-dichlorodihydrofluorescein diacetate cellular-based assay	[PMID: 12762791]
J774	IC₅₀	>500 μM Compound: 1	Cytotoxicity against mouse J774 cells by MTT assay Cytotoxicity against mouse J774 cells by MTT assay	[PMID: 17627828]
Lymphocyte	EC₅₀	>500 nM Compound: alpha-TOH	Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis Anti-ferroptotic activity in FRDA patient-derived Lymphocyte assessed as reduction in RSL3-induced lipid peroxidation incubated for overnight followed by RSL3 stimulation and measured after 90 mins by FACS analysis	[PMID: 33214825]
MCF7	IC₅₀	>300 μM Compound: alpha-TOH	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
MCF7	IC₅₀	329 μM Compound: 1 (alpha-TOH)	Compound was tested for antiproliferative activity against human breast cancer cell line MCF-7 in MTT assay Compound was tested for antiproliferative activity against human breast cancer cell line MCF-7 in MTT assay	[PMID: 9873556]
MT4	IC₅₀	165 μM Compound: alpha-TOH	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
RPMI-8226	IC₅₀	>300 μM Compound: alpha-TOH	Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]
THP-1	IC₅₀	>500 μM Compound: 1	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 17627828]
U-937	IC₅₀	100 μM Compound: alpha-TOH	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27344490]

In Vitro

α-Vitamin E ((+)-α-Tocopherol) is a peroxyl radical scavenger. The importance of this function is to maintain the integrity of long-chain polyunsaturated fatty acids in the membranes of cells and thus maintain their bioactivity^[1].
α-Vitamin E ((+)-α-Tocopherol) has been described to inhibit PKC in various cell types with consequent inhibition of platelet aggregation, endothelial cell nitric oxide production and superoxide production in neutrophils and macrophages. α-Vitamin E ((+)-α-Tocopherol) exposure induced the activation of both the MAP kinase and PI3 kinase (PI3K) pathways, suggesting that it is the oxidative stress that up-regulates kinase pathways and the antioxidant action of α-tocopherol protects the cell membrane fatty acids^[1].
α-Vitamin E ((+)-α-Tocopherol) has proposed benefits for influenza virus A infection, as well as possible activity against hepatitis B and C. α-Vitamin E shows proviral effects, particularly in HEK293T/17 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

α-Vitamin E ((+)-α-Tocopherol) prevents the increase in the pro-inflammatory cytokines IL-1, IL-6, and IFN-γ mRNA and protein compared with the ischemic-reperfused myocardium from untreated pigs and compared to the non-injured area^[1].
α-Vitamin E (D-α-Tocopherol; intraperitoneal injection or oral administration) treatment induces an amelioration of diabetic nephropathy in mice through the activation of diacylglycerol kinase α (DGKα) and the prevention of podocyte loss^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Masse moléculaire

430.71

Formule

C₂₉H₅₀O₂

CAS No.

59-02-9

Appearance

Liquid (Density: 0.95 g/cm³)

Color

Colorless to light yellow

SMILES

OC1=C(C)C(C)=C2C(CC[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)O2)=C1C

Structure Classification

Initial Source

Endogenous metabolite

Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (232.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 100 mg/mL (232.17 mM)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3217 mL	11.6087 mL	23.2175 mL
5 mM	0.4643 mL	2.3217 mL	4.6435 mL
10 mM	0.2322 mL	1.1609 mL	2.3217 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 5 mg/mL (11.61 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation

Purity: 99.67%

Fiche technique (272 KB) SDS (396 KB)

COA (242 KB) HNMR (275 KB) RP-HPLC (258 KB) MS (115 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Maret G Traber, et al. Vitamin E, antioxidant and nothing more. Free Radic Biol Med. 2007 Jul 1;43(1):4-15. [Content Brief]

[2]. Daiki Hayashi, et al. Amelioration of diabetic nephropathy by oral administration of d-α-tocopherol and its mechanisms. Biosci Biotechnol Biochem. 2018 Jan;82(1):65-73. [Content Brief]

[3]. Atchara Paemanee, et al. Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity. BMC Res Notes. 2018 May 16;11(1):307. [Content Brief]

Vous serez peut-être également intéressé par les produits suivants :

Référence

Description

Cond.

Prix HT

AB0021-500g

L-Ascorbic acid ( Vitamin C)

500g

A17696-100

Vitamin A [68-26-8]

100mg

HY-14649-100mg

Retinoic acid [302-79-4]

100mg

α-Vitamin E [59-02-9]

Référence HY-N0683-1g

Marque : MedChemExpress

α-Vitamin E Related Antibodies

Vous serez peut-être également intéressé par les produits suivants :